Cancer Drug Costs Need to Drop
While the skyrocketing drug prices may be driving the cost of cancer care, some doctors and other sectors say the costs associated with hospital care need to be addressed as well. The pharmaceutical industry contends that, based on research data, drugs and chemotherapy only account for 20 percent of the cost of cancer care and one percent of all healthcare spending.
Ted Okon, executive director of the non-profit Community Oncology Alliance, argues that doctors should be addressing the overall cost of cancer care, not just the price of chemotherapy and medications. "I believe that the 118 oncologists have every right to raise the issue of drug pricing, (but) they have to realise that the drug price is only part of the equation," he points out.
The oncologists who published their manifesto online in the journal Mayo Clinic Proceedings are affiliated with some of the most prestigious hospitals in cancer care and research, including the University of Texas MD Anderson Cancer Center in Houston, the Dana Farber Cancer Institute in Boston, and Memorial Sloan Kettering Cancer Center in New York City.
Faced with high costs and copays, the oncologists note that "Patients with cancer then have to make difficult choices between spending their incomes (and liquidating assets) on potentially lifesaving therapies or foregoing treatment to provide for family necessities (food, housing, education)." They call for a "cancer patient-based grassroots movement" to push for changes to allow Medicare to negotiate drug prices and allow patients to import lower cost drugs from Canada.
In addition to drugs, the cost of cancer care can include surgery, lab tests, office visits, and imaging. In 2014, doctors at MD Anderson treated 127,00 patients, performed 69,506 hours of surgery and ordered 12 million lab tests and more than a half million diagnostic imaging procedures.
Okon's organisation represents oncologists who practice outside of the hospital setting. He says that the hospital-based doctors who signed on to the Mayo article should recognise and address not just the cost of drugs, but the cost of services such as inpatient and emergency department care. His critique also comes at a time when oncologists, like other specialists, are closing private practices and affiliating with hospitals.
For his part, Dr. Lowell E. Schnipper, clinical director of the Beth Israel Deaconess Cancer Center, says the issue of cancer care costs is "really complex. The short answer is that the rising costs associated with cancer care are multifactorial."
Drugs may not be the driving factor in cancer costs, Dr. Schnipper notes, but the price of medications is increasing much more rapidly on an annual basis than the cost of any other aspect of cancer care.
Source: Mayo Clinic Proceedings
Image credit: Flickr.com
Published on : Sat, 8 Aug 2015
Print as PDF
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...
Based on the long-established and reliable OTF/AS cryostat, the new OTF5000 brings the extensive range of Bright cryostats completely up to date. New styling coupled with improved user ergonomics, the latest blade systems in the ever-reliable and powerful...
The HAMILTON-T1 combines for the first time the functionality of a fully featured intensive care unit ventilator with the compactness and ruggedness required for transport. This is why the HAMILTON-T1 enables you to provide optimal ventilation therapy...
The HAMILTON-C3 ventilator is a modular high-end ventilation solution for all patient groups. Offering a number of unique features, the HAMILTON-C3 is one of the first ventilators featuring the “Ventilation Autopilot” INTELLiVENT-ASV®. The HAMILTON-C3’s...